Get the Stockscreener App
2.78
1.09%
0.03
After Hours:
2.78
Akebia Therapeutics Inc stock is traded at $2.78, with a volume of 2.40M.
It is up +1.09% in the last 24 hours and down -5.76% over the past month.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.
See More
Previous Close:
$2.75
Open:
$2.77
24h Volume:
2.40M
Relative Volume:
0.69
Market Cap:
$737.10M
Revenue:
$194.75M
Net Income/Loss:
$-51.26M
P/E Ratio:
-9.9286
EPS:
-0.28
Net Cash Flow:
$-23.38M
1W Performance:
-6.40%
1M Performance:
-5.76%
6M Performance:
+68.48%
1Y Performance:
+110.61%
1-Day Range:
$2.69
$2.81
1-Week Range:
$2.69
$3.02
52-Week Range:
$1.30
$4.0787
Akebia Therapeutics Inc Stock (AKBA) Company Profile
Name
Akebia Therapeutics Inc
Sector
Phone
617-871-2098
Address
245 FIRST STREET, CAMBRIDGE, MA
Compare AKBA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AKBA
Akebia Therapeutics Inc
|
2.78 | 729.15M | 194.75M | -51.26M | -23.38M | -0.28 |
|
ZTS
Zoetis Inc
|
142.26 | 62.54B | 9.39B | 2.62B | 2.22B | 5.8121 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.72 | 43.30B | 29.96B | 957.25M | 4.77B | 0.2956 |
|
HLN
Haleon Plc Adr
|
9.08 | 40.08B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
20.02 | 22.98B | 16.70B | -157.13M | 1.19B | -0.1446 |
|
UTHR
United Therapeutics Corp
|
440.06 | 19.90B | 3.08B | 1.24B | 1.07B | 25.61 |
Akebia Therapeutics Inc Stock (AKBA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-04-25 | Resumed | H.C. Wainwright | Buy |
| Apr-28-25 | Initiated | Leerink Partners | Outperform |
| Apr-01-25 | Initiated | Jefferies | Buy |
| Nov-29-23 | Resumed | BTIG Research | Buy |
| Aug-28-23 | Upgrade | H.C. Wainwright | Neutral → Buy |
| May-31-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Mar-31-22 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Mar-31-22 | Downgrade | Mizuho | Buy → Neutral |
| Mar-31-22 | Downgrade | Needham | Buy → Hold |
| Mar-31-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Mar-08-21 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-29-21 | Downgrade | JP Morgan | Neutral → Underweight |
| Nov-14-19 | Reiterated | Needham | Buy |
| Aug-06-19 | Reiterated | H.C. Wainwright | Buy |
| Jul-11-19 | Reiterated | H.C. Wainwright | Buy |
| May-02-19 | Initiated | JP Morgan | Overweight |
| Mar-20-19 | Initiated | Citigroup | Neutral |
| Sep-07-18 | Resumed | Morgan Stanley | Equal-Weight |
| Aug-10-18 | Reiterated | Needham | Buy |
| Jun-06-18 | Reiterated | H.C. Wainwright | Buy |
| Dec-19-17 | Initiated | Piper Jaffray | Overweight |
| Dec-07-17 | Initiated | BTIG Research | Buy |
| Sep-15-17 | Initiated | RBC Capital Mkts | Sector Perform |
| Jul-10-17 | Reiterated | H.C. Wainwright | Buy |
| Apr-27-17 | Reiterated | H.C. Wainwright | Buy |
| Apr-27-17 | Reiterated | Needham | Buy |
| Dec-27-16 | Reiterated | H.C. Wainwright | Buy |
| Dec-20-16 | Reiterated | JMP Securities | Mkt Outperform |
| Nov-15-16 | Initiated | Aegis Capital | Buy |
| Sep-29-16 | Initiated | Brean Capital | Buy |
| Mar-16-16 | Reiterated | Needham | Buy |
| Jan-21-16 | Initiated | Credit Suisse | Neutral |
View All
Akebia Therapeutics Inc Stock (AKBA) Latest News
Applying Elliott Wave Theory to Akebia Therapeutics Inc.2025 Technical Overview & Weekly High Return Stock Forecasts - newser.com
What makes Akebia Therapeutics Inc. stock attractive to growth fundsJuly 2025 Action & Community Consensus Picks - newser.com
How rising interest rates impact Akebia Therapeutics Inc. stockInsider Selling & Weekly Top Gainers Trade List - newser.com
Real time breakdown of Akebia Therapeutics Inc. stock performanceJuly 2025 PostEarnings & Safe Capital Investment Plans - newser.com
Is this a good reentry point in Akebia Therapeutics Inc.Chart Signals & High Win Rate Trade Tips - newser.com
Applying chart zones and confluence areas to Akebia Therapeutics Inc.Quarterly Market Summary & Daily Oversold Stock Bounce Ideas - newser.com
What to expect from Akebia Therapeutics Inc. in the next 30 daysCPI Data & Fast Gaining Stock Strategy Reports - newser.com
Akebia Therapeutics Achieves Multibagger Status with 123.31% Stock Increase Over Past Year - Markets Mojo
Should I hold or sell Akebia Therapeutics Inc. stock in 2025Market Movers & Daily Volume Surge Trade Alerts - newser.com
Can technical indicators confirm Akebia Therapeutics Inc.’s reversalJuly 2025 PreEarnings & Real-Time Volume Surge Alerts - newser.com
What machine learning models say about Akebia Therapeutics Inc.Quarterly Trade Summary & High Win Rate Trade Tips - newser.com
How Akebia Therapeutics Inc. stock performs in interest rate cycles2025 Risk Factors & Growth-Oriented Investment Plans - newser.com
Why Akebia Therapeutics Inc. (AX9) stock is a strong buy callQuarterly Portfolio Summary & Smart Allocation Stock Tips - newser.com
How Akebia Therapeutics Inc. stock reacts to inflationary pressuresTrade Ideas & Fast Exit and Entry Strategy Plans - newser.com
Published on: 2025-10-09 05:00:40 - newser.com
Can Akebia Therapeutics Inc. (AX9) stock resist broad market declinesQuarterly Trade Summary & AI Powered Market Entry Ideas - newser.com
How Akebia Therapeutics Inc. (AX9) stock moves in volatile trading sessions2025 Institutional Moves & Daily Chart Pattern Signals - newser.com
Weiss Ratings Reiterates Sell (D-) Rating for Akebia Therapeutics (NASDAQ:AKBA) - MarketBeat
Is Intellia Therapeutics (NTLA) Outperforming Other Medical Stocks This Year? - Yahoo Finance
Akebia Therapeutics, Inc.'s (NASDAQ:AKBA) Profit Outlook - simplywall.st
What drives Akebia Therapeutics Inc stock priceInsider Buying Signals & Free Daily Market Summary and Trend Reports - earlytimes.in
Published on: 2025-10-03 06:28:34 - newser.com
Is Akebia Therapeutics Inc. stock poised for growthRate Hike & Weekly High Conviction Ideas - newser.com
Will Akebia Therapeutics Inc. (AX9) stock profit from AI boom2025 Major Catalysts & Free Growth Oriented Trading Recommendations - newser.com
Leading vs lagging indicators on Akebia Therapeutics Inc. performanceJuly 2025 Sector Moves & Reliable Breakout Forecasts - newser.com
Is Akebia Therapeutics Inc. stock entering bullish territoryJuly 2025 Technicals & Community Trade Idea Sharing Platform - newser.com
Is Akebia Therapeutics Inc. (AX9) stock attractive for dividend growthWeekly Trend Report & AI Based Trade Execution Alerts - newser.com
Why ETFs are accumulating Akebia Therapeutics Inc. (AX9) stockProfit Target & Fast Exit/Entry Strategy Plans - newser.com
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
204,163 Stock Options: Akebia Therapeutics Awards New Employee Grants with 4-Year Vesting Terms - Stock Titan
Published on: 2025-10-01 08:27:07 - newser.com
Akebia Therapeutics Inc Stock (AKBA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.42%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):